Financings Of The Fortnight Spies The Debuts Of Five New Health Care Funds
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus news on recent financings by InterMune, Orphazyme, Valeritas and Crescendo Bioscience.
You may also be interested in...
Financings Of The Fortnight: Is Merck Joining Other Recent Entrants Into Corporate Venture?
Plus news on recent financings by Acetylon, Tengion, Advanced BioHealing and SymBio Pharmaceuticals.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.